Topic: How To Invest

Power Growth Investor Hotline – Friday, April 19, 2024

Article Excerpt

ELI LILLY AND COMPANY, $726.31, is a buy. The drugmaker (symbol LLY on New York) discovers, develops, manufactures, and markets human pharmaceutical products. This week, Lilly announced that its popular weight loss drug, Zepbound, seems to help people with obstructive sleep apnea. Based on results from trials in people with sleep apnea, the company said it plans to submit the material to the U.S. Food and Drug Administration (FDA) to potentially expand the use of Zepbound for obstructive sleep apnea. Obstructive sleep apnea is a disorder that causes people to briefly stop breathing while they are sleeping, sometimes several times an hour. This condition can keep a person from feeling fully rested because their brain wakes them up when the body senses that they are no longer breathing. The disorder can also make people more prone to developing other serious health problems such as coronary heart disease, heart failure and stroke. The World Health Organization estimates about 100 million people have this disorder. The FDA…